Array BioPharma to Use Horizon Discovery's X-MAN Lines | GenomeWeb

NEW YORK (GenomeWeb News) – Horizon Discovery said today that Array BioPharma will use its X-MAN human isogenic cell lines to evaluate a target that could be used as a cancer treatment.

Array will evaluate a panel of the X-MAN cell lines carrying specific mutant cancer genes with matched parental genetic backgrounds. Array aims to study the potential utility of its compounds and will share some of the data it generates over the course of the evaluation period, which starts this month.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.